ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Bluejay Diagnostics Inc

Bluejay Diagnostics Inc (BJDX)

0.1342
0.0007
(0.52%)
Closed October 04 4:00PM
0.134
-0.0002
(-0.15%)
After Hours: 7:41PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.134
Bid
0.1305
Ask
0.1352
Volume
1,689,345
0.1269 Day's Range 0.1359
0.1161 52 Week Range 38.96
Market Cap
Previous Close
0.1335
Open
0.1349
Last Trade Time
Financial Volume
$ 222,621
VWAP
0.131779
Average Volume (3m)
2,150,527
Shares Outstanding
6,252,192
Dividend Yield
-
PE Ratio
-0.09
Earnings Per Share (EPS)
-1.59
Revenue
-
Net Profit
-9.95M

About Bluejay Diagnostics Inc

Bluejay Diagnostics Inc develops, manufactures and markets innovative clinical diagnostic products that improve the quality of medical diagnoses by developing Point-of-Care tests that provide convenience, timeliness, compliance and low cost to physicians and patients in areas where timeliness of the... Bluejay Diagnostics Inc develops, manufactures and markets innovative clinical diagnostic products that improve the quality of medical diagnoses by developing Point-of-Care tests that provide convenience, timeliness, compliance and low cost to physicians and patients in areas where timeliness of the initial triage assessment has a high impact on course of treatment. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Wilmington, Delaware, USA
Founded
-
Bluejay Diagnostics Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker BJDX. The last closing price for Bluejay Diagnostics was $0.13. Over the last year, Bluejay Diagnostics shares have traded in a share price range of $ 0.1161 to $ 38.96.

Bluejay Diagnostics currently has 6,252,192 shares outstanding. The market capitalization of Bluejay Diagnostics is $834,667.63 . Bluejay Diagnostics has a price to earnings ratio (PE ratio) of -0.09.

BJDX Latest News

Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony...

Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering

ACTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony...

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

ACTON, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced results from the primary analysis of SYMON-I, a multicenter pilot clinical study...

Bluejay Diagnostics Announces Reverse Stock Split

ACTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0049-3.527717782580.13890.14480.116121702040.13109873CS
4-0.019-12.41830065360.1530.1650.116111645460.13989953CS
12-0.4505-77.07442258340.58450.750.116121505270.36004998CS
26-5.626-97.67361111115.766.33840.116112888710.92126481CS
52-30.026-99.555702917830.1638.960.11616713911.28375252CS
156-875.066-99.9846892139875.210000.1161779391157.07700143CS
260-875.066-99.9846892139875.210000.1161779391157.07700143CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CHSNChanson International Holding
$ 11.22
(269.08%)
14.71M
PEVPhoenix Motor Inc
$ 1.0607
(205.24%)
228.32M
ENTOEntero Therapeutics Inc
$ 0.60
(72.20%)
10.41M
BENFBeneficient
$ 1.8914
(58.94%)
108.29M
FORDForward Industries Inc
$ 5.3254
(52.15%)
18.44M
ADDColor Star Technology Company Ltd
$ 0.2701
(-39.98%)
14.96M
DUOFangDD Network Group Ltd
$ 2.53
(-32.89%)
28.48M
ICCTiCoreConnect Inc
$ 0.4102
(-31.50%)
1.68M
ZENAZenaTech Inc
$ 3.91
(-29.55%)
213.24k
SPAISafe Pro Group Inc
$ 1.93
(-25.77%)
239.89k
NVDANVIDIA Corporation
$ 124.92
(1.68%)
244.36M
PEVPhoenix Motor Inc
$ 1.0607
(205.24%)
228.32M
SQQQProShares UltraPro Short QQQ
$ 7.43
(-3.63%)
184.39M
NCNCnoco noco Inc
$ 0.144
(8.60%)
147.29M
BENFBeneficient
$ 1.8914
(58.94%)
108.29M

BJDX Discussion

View Posts
mining101 mining101 4 hours ago
Seems ready
👍️0
mining101 mining101 3 weeks ago
Anytime ready
👍️0
Arnold25764 Arnold25764 1 month ago
Okay thanks
👍️0
jelaco jelaco 1 month ago
Yup, r/s coming soon - Pre 14A dropped Friday
👍️0
mining101 mining101 1 month ago
Super rebound next week?
👍️0
DK11 DK11 1 month ago
.18 dip
👍️0
tw0122 tw0122 1 month ago
.19 dip
👍️0
tw0122 tw0122 1 month ago
August 28, 2024, Nasdaq’s Listing Qualifications Staff notified the Company that it has extended the time period for the Company to regain compliance with the Minimum Bid Requirement until February 24, 2025. To regain compliance, the closing bid price of the Common Stock must be at least $1.00 or higher for a minimum of ten consecutive business days.

The Company intends to continue to actively monitor the closing bid price of the Common Stock and will evaluate available options to regain compliance with the Minimum Bid Requirement. Specifically, the Company has confirmed to Nasdaq that, if necessary, it will implement a reverse stock split of its outstanding common stock (if approved by the Company’s stockholders) to attempt to regain compliance. If the Company does not regain compliance within the additional compliance period, Nasdaq will provide notice that the Common Stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Requirement during the 180-day additional compliance period or maintain compliance with the other Nasdaq listing requirements.
👍️0
tw0122 tw0122 1 month ago
3.6m shares traded whole float interesting
👍️0
tw0122 tw0122 1 month ago
Hedgies loading down here News must be around the corner. Unusual volume
👍️0
tw0122 tw0122 1 month ago
Pounded down by hedgies no mercy .. . Last offering at $1.63 long ways up..
The purchase price of each Common Unit is $1.63, and the purchase price of each Prefunded Unit is $1.6299 (which is equal to the public offering price per Common Unit minus $0.0001). The Prefunded Warrants will be immediately exercisable and may be exercised at any time until all the Prefunded Warrants are exercised in full.
The Class C Warrants, which will not be exercisable until approval by the Company’s stockholders, will have an initial exercise price of $1.96 per share, and will expire five (5) years from the date of such stockholder approval. Each Class D Warrant will be exercisable immediately. The exercise price and number of shares of Common Stock issuable under the Class D Warrants are subject to adjustment as described in the Class D Warrant. The Company intends to use the net proceeds from the offering to (i) repay $2.3 million in outstanding debt that will be due and payable upon consummation of the offering and (ii) fund matters related to obtaining FDA approval (including clinical studies related thereto), as well as for other research and development activities, and for general working capital needs.
👍️0
tw0122 tw0122 1 month ago
Bottom feeder at .20-.22 let’s go some still relatively low floater
👍️0
Arnold25764 Arnold25764 1 month ago
Any possible catalyst?
👍️0
DK11 DK11 1 month ago
This stock sucks!!!
👍️0
mining101 mining101 1 month ago
Looks like bottom is found
👍️0
shurtha2000 shurtha2000 1 month ago
C'mon Drop that SYMON - II study for Sepsis
👍️0
Monksdream Monksdream 2 months ago
BJDX new 52=week low
👍️0
Arnold25764 Arnold25764 2 months ago
Chance for an r/s anytime soon here?
👍️0
glenn1919 glenn1919 2 months ago
BJDX..............................https://stockcharts.com/h-sc/ui?s=BJDX&p=W&b=5&g=0&id=p86431144783
👍️0
mining101 mining101 2 months ago
Brewing
👍️0
Monksdream Monksdream 2 months ago
BJDX new 52 week low
👍️0
Law of Averages Law of Averages 2 months ago
BJDX looks like it wants to make a move here.
👍️0
Monksdream Monksdream 2 months ago
BJDX new 52 week low
👍️0
Law of Averages Law of Averages 2 months ago
This looks like a double bottom pattern at .53
👍️0
mining101 mining101 3 months ago
Recovering soon?
👍️0
Monksdream Monksdream 3 months ago
BJDX new 52 week low
👍️0
Monksdream Monksdream 3 months ago
BJDX new 52 week low
👍️0
Monksdream Monksdream 3 months ago
BJDX new 52 week low
👍️0
Monksdream Monksdream 3 months ago
BJDX new 52 week low
👍️0
PonkenPlonken PonkenPlonken 3 months ago
I am surprised they were able to make it move with this PR.
👍️0
Awl416 Awl416 3 months ago
That was quick

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients
👍️0
Monksdream Monksdream 3 months ago
Whoops, I did it, again
👍️0
glenn1919 glenn1919 3 months ago
BJDX.................................https://stockcharts.com/h-sc/ui?s=BJDX&p=W&b=5&g=0&id=p86431144783
👍️0
richrichrich richrichrich 3 months ago
Yes......Sad but true.....
I wish the SEC would change the rules, about doing a RS......Make it really hard to get permission......
Sorry.....Your only other choices are to create more shares, de=list, or die.....
JMO
👍️0
tw0122 tw0122 3 months ago
Reverse split $2.71 keep an eye next few weeks for bottom
👍️0
glenn1919 glenn1919 4 months ago
BJDX...............................https://stockcharts.com/h-sc/ui?s=BJDX&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 4 months ago
BJDX another round .54
👍️0
tw0122 tw0122 4 months ago
BJDX on its way back to the Moon
👍️0
Monksdream Monksdream 6 months ago
BJDX new 52 lo
👍️0
Monksdream Monksdream 6 months ago
BJDX new 52 lo
👍️0
Monksdream Monksdream 6 months ago
BJDX 10Q due 4/21
👍️0
Monksdream Monksdream 9 months ago
BJDX new 52 week low
👍️0
Monksdream Monksdream 9 months ago
BJDX new 52 week low
👍️0
Monksdream Monksdream 10 months ago
BJDX new 52 week low
👍️0
jobynimble jobynimble 11 months ago
Press release on eps: https://www.sec.gov/Archives/edgar/data/1704287/000121390023085197/ea187862ex99-1_bluejay.htm

Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results

Acton, Massachusetts, November 9, 2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its financial results for the quarter and nine months ended September 30, 2023.

“Based on FDA’s feedback from the August 11, 2023, meeting, the Company focused on implementing the modified clinical strategy that puts us on the most efficient pathway and believes that it would submit for regulatory approval for Symphony IL-6 during the first half of 2024 as planned. Furthermore, we have re-negotiated our licensing agreement with Toray Industries, Inc. to include a reduced royalty payment from 15% to 7.5% of net sales of certain cartridges for a term of 10 years. A 50% reduction in the royalty rate applies upon expiry of applicable Toray patents on a product-by-product and country-by-country basis. The new license agreement contemplates that applicable royalty payment obligations from the Company to Toray for other products will be determined separately by the parties in the future. Overall, the re-negotiated licensing agreement provides Bluejay with more freedom to operate, and better secures long-term licensing of Toray’s patents and know-how around the Symphony technology In addition, we have re-negotiated our supply agreement with Toray Industries, Inc. to ensure critical Symphony Cartridge component supply that will sustain us through clinical studies,” said Neil Dey, CEO of Bluejay Diagnostics.

Symphony IL-6 has the potential to be an influential tool for the prediction of clinical deterioration in sepsis patients. Symphony IL-6 testing, in conjunction with clinical and other diagnostic findings, may enable healthcare providers to better prioritize appropriate care to help improve outcomes for those at high risk, and potentially avoid unnecessary investigations and treatments in those at low risk. IL-6 appears as a ‘first responder’ inflammatory biomarker in blood during inflammation, which is common in diseases and infections. A current unmet challenge for healthcare professionals is the amount of time it takes to identify sepsis in patients and to determine disease severity. Existing technologies typically take several hours to deliver IL-6 results, which can delay critical treatment decisions that could improve patient outcomes.

“We are confident that our planned clinical and analytical studies may support a 510(k) FDA regulatory submission with an initial indication for risk stratification of hospitalized sepsis patients. In order for us to realize this, we have continued to limit our cash burn while executing our clinical and regulatory strategy for the Symphony IL-6 test,” said Neil Dey, CEO of Bluejay Diagnostics.

Financial Results for the Three Months Ended September 30, 2023

Cash and cash equivalents. Cash and cash equivalents on September 30, 2023 were $5.08 million, as compared to $10.1 million on December 31, 2022. The Company has maintained a slow cash burn during its FDA submission process. The Company estimates cash resources will be sufficient to fund its operations into the first quarter of 2024. The Company will need additional capital to fund its planned operations for the next 12 months. The Company expects that it will seek to raise such additional capital through public or private equity offerings, grant financing and support from governmental agencies, convertible debt, collaborations, strategic alliances and distribution arrangements.

Research and development expense. Research and development expenses for the three and nine months ended September 30, 2023 were $1.39 million and $4.42 million, respectively, as compared to $1.37 million and $2.83 million, respectively, for the comparable periods in 2022. The increase in research and development expenses is due to the expansion of our clinical program and to support scale-up manufacturing of the Symphony technology platform and IL-6 Test.

General and administrative expense. General and administrative expenses for the three and nine months ended September 2023 were $0.96 million and $3.21 million, respectively, as compared to $1.28 million and $3.8 million, respectively, for the comparable periods in 2022. The decrease in general and administrative expenses reflects the Company’s focus on clinical program and manufacturing scale-up.

Sales and marketing expense. Sales and marketing expenses for the three and nine months ended September 30, 2023 were $(19,619) and $282,756, respectively, as compared to $146,102 and $281,144, respectively, for the comparable periods in 2022. While these expenses have been limited to date, we expect to increase these efforts when appropriate to support our commercial growth.

Net loss/Net loss per share. The net loss for the three and nine months ended September 30, 2023 was $2.29 million and $7.65 million, or $2.08 and $7.30 per share, respectively, compared to $2.9 million and $6.9 million, or $2.94 and $6.86 per share, respectively, for the comparable periods in 2022.

About the SymphonyTM System:

Bluejay’s Symphony System (the “Symphony System”) is designed to address the need for simple, reliable, rapid, near-patient testing by providing quantitative measurements of specific biomarkers to determine the need for additional patient care and monitoring. The user-friendly Symphony System will not require any sample preparation or dedicated staff and was shown in published clinical studies to deliver results in approximately 20 minutes.

The Symphony IL-6 Test is a development stage product candidate for investigational use only. It is limited by United States law to investigational use.

About Bluejay Diagnostics:

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for triage and monitoring of disease progression. Bluejay’s first product candidate, an IL-6 Test for sepsis triage, is designed to provide accurate, reliable results in approximately 20 minutes from ‘sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.

Forward-Looking Statements:

This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements in this press release include, without limitation, the ability of the Company to submit a marketing application with the FDA in the first-half of 2024 whether the Company’s cash position will be sufficient to fund operations beyond the date of its anticipated regulatory approval and initial commercialization of the Symphony IL-6 Test, and whether such anticipated regulatory approval will actually occur. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest”, “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission, as updated by the Company’s subsequent Quarterly Reports on Form 10-Q. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events.

Investor Contact:
Neil Dey
Bluejay Diagnostics, Inc.
Tel: 978-631-0310
Email: neil.dey@bluejaydx.com
👍️0
jobynimble jobynimble 11 months ago
8-K: https://www.sec.gov/ix?doc=/Archives/edgar/data/1704287/000121390023085197/ea187862-8k_bluejay.htm

Item 2.02 Results of Operations and Financial Condition.

On November 9, 2023, Bluejay Diagnostics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2023 and a corporate update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description
99.1 Press release dated November 9, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
👍️0
jobynimble jobynimble 11 months ago
10-Q out…

https://www.sec.gov/Archives/edgar/data/1704287/000121390023085215/f10q0923_bluejay.htm
👍️0
make it happen make it happen 1 year ago
This will lose a decimal point and will be doing another one in my honest opinion
👍️0
Invest-in-America Invest-in-America 1 year ago
BJDX: I myself made it SOAR --- vis-a-vis my PSYCHO (excuse me, PSYCHIC) powers!!!!



Sincerely yours,
That-Nut-Job
San Diego, CA
👍️0
subslover subslover 1 year ago
Been searching everywhere and can't find news or any reason for this explosion.
👍️0

Your Recent History

Delayed Upgrade Clock